Either you do not have the newest version of Adobe Flash®, or you have JavaScript disabled.

Please ensure you have these capabilities.


Remicalm's Identafi™ technologies include numerous issued and pending patents relating to the detection of various types of pre-cancerous conditions (dysplasia) and cancers. Detection is made through the processing of optical fluorescence and reflectance in certain body tissues.

The Identafi™ core technologies are based on high-speed, high-resolution capabilities developed from patented optical processing technology and includes the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.

The Identafi™ core technologies provide for the development and introduction of a suite of cancer screening and diagnostic products. These screening and diagnostic products are housed in a small portable, handheld, cordless unit designed for use in the offices of physicians, dentists, specialists and general practitioners for the screening and diagnosing of cancers and pre-cancerous lesions.

Products now in development will be able to detect pre-cancerous cells and cancers in specific areas of the body including, but not limited to,

  • Oral (the mouth, throat, tongue and tonsils),
  • Cervical,
  • Gastrointestinal
    • Barrett's Esophagus
    • Esophageal Cancer
  • Skin
    • Basal Cell Cancer
    • Squamous Cell Cancer
    • Melanoma